PHARMACOKINETIC AND PHARMACODYNAMIC MODELING OF ARQ 087, A NOVEL PAN-FGFR INHIBITOR, IN PATIENTS WITH ADVANCED SOLID TUMORS, INCLUDING INTRAHEPATIC CHOLAN-GIOCARCINOMA.

被引：0
|
作者：
Savage, R. [1 ]
Trinh, M. [2 ]
Dupuis, M. [2 ]
Marier, J. F. [2 ]
Schwartz, B. [1 ]
机构：
[1] ArQule, Burlington, MA USA
[2] Certara Strateg Consulting, Montreal, PQ, Canada
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2017年 / 101卷 / S1期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
PII-091
引用
收藏
页码：S77 / S77
页数：1
相关论文
共 50 条
  • [41] Phase I safety, pharmacokinetic and pharmacodynamic trial of BMS-599626 (AC480), an oral pan-HER receptor tyrosine kinase inhibitor, in patients with advanced solid tumors
    Soria, J-C
    Cortes, J.
    Massard, C.
    Armand, J-P
    De Andreis, D.
    Ropert, S.
    Lopez, E.
    Catteau, A.
    James, J.
    Marier, J-F
    Beliveau, M.
    Martell, R. E.
    Baselga, J.
    ANNALS OF ONCOLOGY, 2012, 23 (02) : 463 - 471
  • [42] First-in-man study of E-3810, a novel VEGFR and FGFR inhibitor, in patients with advanced solid tumors.
    Soria, J.
    De Braud, F. G.
    Cereda, R.
    Bahleda, R.
    Delmonte, A.
    Angevin, E.
    Varga, A.
    Noberasco, C.
    Dall'O, E.
    Lassau, N.
    Dromain, C.
    Bellomi, M.
    Farace, F.
    Bertolini, F.
    Zucchetti, M.
    Marsoni, S.
    Camboni, M. G.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [43] Phase I clinical, pharmacokinetic, and pharmacodynamic study of SB939, an oral histone deacetylase inhibitor (HDACi), in patients with advanced solid tumors
    Siu, Lillian L.
    Hotte, Sebastien J.
    Chen, Eric X.
    Hirte, Hal W.
    Powers, Jean
    Stayner, Lee-Anne
    Lacobucci, Anne
    Novotny-Diermayr, Veronica
    Zhu, Joy
    Eisenhauer, Elizabeth A.
    MOLECULAR CANCER THERAPEUTICS, 2009, 8 (12)
  • [44] Phase I Pharmacokinetic/Pharmacodynamic Study of MLN8237, an Investigational, Oral, Selective Aurora A Kinase Inhibitor, in Patients with Advanced Solid Tumors
    Cervantes, Andres
    Elez, Elena
    Roda, Desamparados
    Ecsedy, Jeffrey
    Macarulla, Teresa
    Venkatakrishnan, Karthik
    Rosello, Susana
    Andreu, Jordi
    Jung, JungAh
    Sanchis-Garcia, Juan Manuel
    Piera, Adelaida
    Blasco, Inma
    Manos, Laura
    Perez-Fidalgo, Jose-Alejandro
    Fingert, Howard
    Baselga, Jose
    Tabernero, Josep
    CLINICAL CANCER RESEARCH, 2012, 18 (17) : 4764 - 4774
  • [45] Inhibition of Autophagy: a Phase 1 Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Analysis of Hydroxychloroguine, in Combination with the HDAC Inhibitor, Vorinostat, in Patients with Advanced Solid Tumors
    Mahalingam, D.
    Mita, M.
    Sarantopoulos, J.
    Amaravadi, R.
    Davis, L.
    Mita, A.
    Curiel, T.
    Nawrocki, S.
    Carew, J.
    EUROPEAN JOURNAL OF CANCER, 2012, 48 : 28 - 28
  • [46] Phase I clinical, pharmacokinetic, and pharmacodynamic study of CG200745, a histone deacetylase (HDAC) inhibitor, in patients with advanced solid tumors.
    Kim, Kyu-Pyo
    Hong, Yong Sang
    Ahn, Jin-Hee
    Lee, Jae-Lyun
    Bae, Kyun-Seop
    Kim, Tae Won
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [47] A phase I pharmacokinetic and pharmacodynamic study of TKI258, an oral, multitargeted receptor tyrosine kinase inhibitor in patients with advanced solid tumors
    Sarker, Debashis
    Molife, Rhoda
    Evans, T. R. Jeffrey
    Hardie, Maryon
    Marriott, Cheryl
    Butzberger-Zimmerli, Priska
    Morrison, Rosemary
    Fox, Judith A.
    Heise, Carla
    Louie, Sharianne
    Aziz, Natasha
    Garzon, Felix
    Michelson, Glenn
    Judson, Ian R.
    Jadayel, Dalal
    Braendle, Edgar
    de Bono, Johann S.
    CLINICAL CANCER RESEARCH, 2008, 14 (07) : 2075 - 2081
  • [48] Pharmacokinetics of the Novel FGFR and VEGFR Inhibitor, E-3810, in Patients with Advanced Solid Tumors Participating to a Phase I/II Trial
    Zangarini, M.
    Sala, F.
    Camboni, M. G.
    Cereda, R.
    Livi, V.
    Bahleda, R.
    Dienstmann, R.
    Delmonte, A.
    D'Incalci, M.
    Zucchetti, M.
    EUROPEAN JOURNAL OF CANCER, 2012, 48 : 183 - 183
  • [49] First-in-human study of highly selective FGFR2 inhibitor, RLY-4008, in patients with intrahepatic cholangiocarcinoma and other advanced solid tumors
    Goyal, L.
    Subbiah, V.
    Mahipal, A.
    Kamath, S.
    Mody, K.
    Borad, M.
    El-Khoueiry, A.
    Sahai, V.
    Kim, R.
    Kelley, R.
    Schmidt-Kittler, O.
    Shen, J.
    Jen, K.
    Deary, A.
    Padval, M.
    Sherwin, C.
    Wolf, B.
    Schram, A.
    ANNALS OF ONCOLOGY, 2021, 32 : S120 - S120
  • [50] A phase I study of BMS-582664 (brivanib alaninate), an oral dual inhibitor of VEGFR and FGFR tyrosine kinases, in patients (pts) with advanced/metastatic solid tumors: Safety, pharmacokinetic (PK), and pharmacodynamic (PD) findings
    Jonker, D. J.
    Rosen, L. S.
    Sawyer, M.
    Wilding, G.
    Noberasco, C.
    Jayson, G.
    Rustin, G.
    McArthur, G.
    Velasquez, L.
    Galbraith, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
12345